High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities
Open Access
- 19 May 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Ductal carcinoma in situ is a non-obligate precursor lesion of breast cancer. Often detected by mammography, most cases are managed through surgical and/or radiotherapy approaches. Today, it is not possible to predict which patients will progress to invasive disease. Here, we evaluate high-depth whole-genome sequenced ductal carcinoma in situ, enriched for high-grade clinical lesions, to understand whether deep WGS could reveal biological insights and/or personalized therapeutic vulnerabilities that may be targetable. We find genomic locations that are likely susceptible to producing the initiating lesion for structural variations prone to subsequent evolution, termed SHOREs. We additionally highlight individualized therapeutic potential that would otherwise not be appreciable without whole genome sequencing. We posit that holistic whole genome sequencing profiling could offer a more precise stratification approach, discerning higher-risk cases for prospective clinical studies on personalized therapies, from truly low-risk cases suitable for active monitoring.Keywords
This publication has 60 references indexed in Scilit:
- Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In SituJAMA, 2025
- DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCISThe Breast, 2024
- Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trialEuropean Journal of Cancer, 2023
- A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progressionCancer Cell, 2023
- Variability in grading of ductal carcinoma in situ among an international group of pathologistsThe Journal of Pathology: Clinical Research, 2021
- The Genomic and Immune Landscapes of Lethal Metastatic Breast CancerCell Reports, 2019
- Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiativeBritish Journal of Surgery, 2018
- Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 womenBreast Cancer Research and Treatment, 2016
- Addressing overtreatment of screen detected DCIS; the LORIS trialEuropean Journal of Cancer, 2015
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012